MDXH

MDXH

MDxHealth SA ADR

Net -79.91%top 1%Rev 76.10%top 1%Revenue grew 100% of years1Y
Hold

MDxHealth SA develops precision diagnostics for urologic conditions, offering non-invasive tests for prostate cancer and urinary tract infections. Its products include Select mdx, Confirm mdx, and Resolve mdx, guiding patient treatment decisions.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 1 year ago โ†’$164today

Score Overview

1 Year
Scoreโ€”
Net Growth-79.91%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth76.10%
Rev TrendGrew
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-6x
Net Trend55%
Net Income Consistency
Rev Growth361x
Rev Trend82%
Revenue Consistency

See the full market ranking โ†’

MDxHealth SA ADR fundamental performance

Across MDxHealth SA ADR's full reported history, from 2004 to 2025, revenue grew from $ 525.97K to $ 107M and net income went from -$ 7M to -$ 33M. Revenue increased in 82% of the years measured; net income in 55%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 0.47โ€”
1 Year2025-08-12
$ 2.87-83.64%
All Time2021-11-04
$ 12.00-96.09%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 189M-$ 60M$ 29M
2025$ 107M-$ 33M$ 29M
2024$ 90M-$ 38M$ 46M
2023$ 70M-$ 43M$ 22M
2022$ 37M-$ 44M$ 15M
IPO2021$ 22M-$ 29M$ 58M
2020$ 18M-$ 28M$ 15M
2019$ 11M-$ 43M$ 22M
2018$ 28M-$ 32M$ 26M
2017$ 40M-$ 12M$ 16M
2016$ 29M-$ 13M$ 30M
2015$ 17M-$ 14M$ 30M
2014$ 11M-$ 15M$ 18M
2013$ 7M-$ 16M$ 24M
2012$ 4M-$ 11M$ 15M
2011$ 3M-$ 9M$ 14M
2010$ 3M-$ 10M$ 14M
2009$ 3M-$ 20M$ 25M
2008$ 4M-$ 14M$ 42M
2007$ 3M-$ 14M$ 48M
2006$ 3M-$ 9M$ 43M
2005$ 3M-$ 5M$ 11M
2004$ 525.97K-$ 7M$ 310.43K

Explore beyond MDXH

You're looking at MDxHealth SA ADR. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies